The paclitaxel-coated device, already approved in Europe and other parts of the world, will be tested on more than 1,200 patients for a new international trial. If the study is a success, Medtronic hopes to gain regulatory approval in the United States and Japan. 

Transfemoral TAVR is not always a viable option. In those instances, the two most effective alternatives are transcarotid access and transcaval access, according to a new SCAI expert consensus statement.

CMS is expected to release a proposed national coverage determination decision memo by July.
 

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

The global medtech company is also looking to expand its organ transplant and ECMO portfolios.

The median follow-up period was more than nine years, allowing researchers to compare long-term outcomes after both CABG and PCI. 

Military veterans face an increased risk of cardiovascular disease, making it especially important to ensure they receive high-quality care.

Other procedures are associated with higher profits—heart transplants, for instance—but CABG and TAVR are performed much more often.